| abstract |
The use of a compound of the formula ** formula ** in which R 1 is hydrogen, deuterium, tritium, C 1-7 alkyl, C 1-7 alkoxy, C 1-7 alkyl, substituted by halogen, C 1-7 alkoxy substituted by halogen , halogen, phenyl optionally substituted by halogen, or is phenyloxy, benzyl, benzyloxy, -COO-C 1-7 alkyl, -O- (CH 2) or O-C 1-7 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl or tetrahydropyran 4-yloxy, said substituents for n> 1 may be the same or different; X is a link, -CHR-, -CHRCHR'-, -OCH2-, -CH2OCHR-, -CH2CH2CH2-, -SCH2-, -S (O) 2CH2-, -CH2SCH2-, - CH2N (R) CH2-, -C3-6-CH2- or SiRR'-CH2- cycloalkyl; R / R 'independently of one another may be hydrogen, C1-7 alkyl or C1-7 alkyl substituted by halogen; R2 is hydrogen, phenyl or C1-7 alkyl; Y is phenyl, naphthyl, thiophenyl, pyridinyl, C3-6 cycloalkyl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 2,3-dihydrobenzo [1,4]-dioxin-6-yl or benzo [ 1,3] dioxol-5-yl; n is the number 0, 1, 2 or 3; or is the number 2 or 3; or to a pharmaceutically acceptable acid addition salt for the manufacture of medicaments for the treatment of diseases related to the biological function of receptors associated with trace amines, such diseases are neurological diseases, neurodegenerative disorders, Alzheimer's disease, epilepsy , migraine, dyslipidemia and disorders of energy consumption and assimilation. |